Vericel FY2024 EPS Estimate Increased by Leerink Partnrs

Vericel Co. (NASDAQ:VCEL) – Leerink Partnrs lifted their FY2024 earnings per share (EPS) estimates for Vericel in a research note issued to investors on Thursday, November 7th. Leerink Partnrs analyst M. Kratky now forecasts that the biotechnology company will post earnings of $0.15 per share for the year, up from their previous estimate of $0.12. The consensus estimate for Vericel’s current full-year earnings is $0.13 per share. Leerink Partnrs also issued estimates for Vericel’s Q4 2024 earnings at $0.33 EPS, Q2 2025 earnings at $0.01 EPS, Q4 2025 earnings at $0.37 EPS, FY2027 earnings at $1.35 EPS and FY2028 earnings at $1.81 EPS.

Vericel (NASDAQ:VCEL) last released its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.05) by $0.03. The firm had revenue of $57.91 million during the quarter, compared to the consensus estimate of $55.32 million. Vericel had a return on equity of 1.48% and a net margin of 1.56%.

Other equities research analysts also recently issued research reports about the company. TD Cowen boosted their price objective on Vericel from $55.00 to $60.00 and gave the company a “buy” rating in a report on Tuesday, August 27th. Stephens boosted their price objective on Vericel from $56.00 to $58.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. Canaccord Genuity Group started coverage on Vericel in a report on Friday, August 9th. They set a “buy” rating and a $57.00 price objective for the company. StockNews.com upgraded Vericel from a “sell” rating to a “hold” rating in a report on Friday. Finally, Truist Financial raised their price objective on Vericel from $56.00 to $57.00 and gave the company a “buy” rating in a research note on Tuesday, July 16th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, Vericel has a consensus rating of “Moderate Buy” and a consensus price target of $57.71.

Vericel Stock Up 5.1 %

NASDAQ VCEL opened at $56.78 on Monday. The company has a market cap of $2.78 billion, a price-to-earnings ratio of 946.49 and a beta of 1.66. Vericel has a 52 week low of $32.31 and a 52 week high of $57.35. The business has a 50 day moving average price of $44.27 and a 200-day moving average price of $46.41.

Insider Activity

In other news, CEO Dominick Colangelo sold 17,500 shares of the company’s stock in a transaction that occurred on Wednesday, October 16th. The stock was sold at an average price of $41.38, for a total value of $724,150.00. Following the completion of the transaction, the chief executive officer now directly owns 220,937 shares of the company’s stock, valued at $9,142,373.06. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, CEO Dominick Colangelo sold 17,500 shares of the company’s stock in a transaction that occurred on Wednesday, October 16th. The stock was sold at an average price of $41.38, for a total value of $724,150.00. Following the completion of the transaction, the chief executive officer now directly owns 220,937 shares of the company’s stock, valued at $9,142,373.06. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Steven C. Gilman sold 5,833 shares of the company’s stock in a transaction that occurred on Wednesday, October 16th. The shares were sold at an average price of $41.36, for a total value of $241,252.88. Following the completion of the transaction, the director now directly owns 11,000 shares of the company’s stock, valued at approximately $454,960. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 29,166 shares of company stock valued at $1,200,764 over the last three months. Corporate insiders own 5.20% of the company’s stock.

Hedge Funds Weigh In On Vericel

Institutional investors and hedge funds have recently bought and sold shares of the company. UniSuper Management Pty Ltd bought a new position in Vericel during the first quarter valued at $595,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its holdings in Vericel by 10.9% during the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,021,695 shares of the biotechnology company’s stock valued at $53,149,000 after purchasing an additional 100,797 shares during the period. Silvercrest Asset Management Group LLC bought a new position in Vericel during the first quarter valued at $6,538,000. Scholtz & Company LLC bought a new position in Vericel during the second quarter valued at $1,357,000. Finally, Allspring Global Investments Holdings LLC boosted its holdings in shares of Vericel by 6.5% in the second quarter. Allspring Global Investments Holdings LLC now owns 420,643 shares of the biotechnology company’s stock worth $19,299,000 after acquiring an additional 25,626 shares during the period.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.